New Two-Drug immune attack launched against tough cancers
NCT ID NCT03860272
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for early signs of tumor shrinkage. About 500 participants with various cancers (including lung, ovarian, and colorectal) are taking part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Botensilimab (AGEN1181) and Balstilimab (AGEN2034)
- What this could lead to
- If this works, it could point toward a new treatment option for several advanced cancers that have not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial, so the main goals are safety and dosing — not yet proving the drugs shrink tumors. The combination may cause significant immune-related side effects, and many early-stage cancer drugs never make it to approval.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Providence Portland Cancer Center
Portland, Oregon, 97213, United States
-
Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California, 90025, United States
-
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
UCLA Santa Monica Hematology Oncology
Los Angeles, California, 90095, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Can your own immune cells beat advanced cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?